In silico Evaluation of the Inhibitory Potential of Novel Hybrid Efflux Pump Inhibitors against Mycobacterium tuberculosis

Résumé fourni par la source

Tuberculosis (TB) is an infectious condition caused by Mycobacterium tuberculosis. One of the key steps towards introducing infectious disease in control is the creation and application of antibiotics. M. tuberculosis strain is multidrug resistant, which is a major threat to TB control. It develops multidrug resistance (MDR) by using efflux pumps (EPs) and other associated systems that can reduce the efficacy of the drug. Several techniques are currently developed to overcome the efflux-mediated resistance and the development of efflux pump inhibitors (EPIs) is one of them. The current study aims to provide an in-silico evaluation of biologically validated hybrid efflux pump inhibitors (HEPIs) with different M. tuberculosis EP proteins. Twelve different HEPIs were identified through literature review. Docking analysis was used to examine the role of HEPI inhibition against 5 MDR EPs. Additionally, the absorption, distribution, metabolism, excretion, and toxicity (ADMET) of all hybrid EP inhibitors were assessed. Molecular docking indicated that several HEPIs, specifically 5, 7, and 11, showed persistent higher binding affinities across multiple proteins, with docking scores comparable to or better than already known inhibitors. The predicted ADMET profiles suggested that most inhibitors had good oral bioavailability and adequate safety margins. To conclude, these HEPIs have the ability to effectively inhibit TB in human beings. In this regard, HEPI-5, HEPI-7, and HEPI-11 were determined as the most promising inhibitors because of their high binding affinities and positive ADMET profiles. Although experimental validation is essential to confirm their therapeutic relevance, these findings highlight their potential as novel EPI scaffolds. However, some of their pharmacological properties are not appropriate for human beings.